19th Aug 2005 06:00
Share Price MovementBasingstoke, UK and Philadelphia, US - August 18, 2005 - Shire PharmaceuticalsGroup plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) notes the recent movement in itsshare price and the speculation regarding possible negotiations between Shireand Barr Pharmaceuticals Inc ("Barr").Shire is currently involved in litigation with Barr concerning Barr's effortsto market a generic version of Shire's ADDERALL XR⨠drug prior to theexpiration of the Shire patents relating to this drug. Shire continues todefend its patents for ADDERALL XR, which are not set to expire prior to 2018.Shire continues to review all options with respect to this litigation, and hasnot ruled out the possibility of settling this litigation or entering into anagreement with Barr that would result in Barr's ability to launch a genericversion of ADDERALL XR prior to 2018. To that end, Shire confirms that therehave been very preliminary discussions with Barr.Given the very preliminary nature of the discussions, it is not possible toform any judgment as to the likelihood of reaching any agreement with Barr.For further information please contact:Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Media Jessica Mann (Rest of the World) +44 1256 894 280 Matthew Cabrey (North America) +1 484 595 8248 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing and marketing products in the areas ofcentral nervous system (CNS), gastrointestinal (GI), and renal diseases. Shirehas operations in the world's key pharmaceutical markets (US, Canada, UK,France, Italy, Spain and Germany) as well as a specialist drug delivery unit inthe US.For further information on Shire, please visit the Company's website: www.shire.com."SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF1995Statements included herein that are not historical facts are forward-lookingstatements. Such forward-looking statements involve a number of risks anduncertainties and are subject to change at any time. In the event such risks oruncertainties materialize, Shire's results could be materially affected. Therisks and uncertainties include, but are not limited to, risks associated withthe inherent uncertainty of pharmaceutical research, product development,manufacturing and commercialization, the impact of competitive products,including, but not limited to, the impact of those on Shire's Attention Deficitand Hyperactivity Disorder (ADHD) franchise, patents, including but not limitedto, legal challenges relating to Shire's ADHD franchise, government regulationand approval, including but not limited to Health Canada's suspension ofADDERALL XR⨠sales in Canada and the expected product approval dates of MTS(METHYPATCH) (ADHD), SPD503 (ADHD), SPD465 (ADHD), SPD476 (ulcerative colitis)and NRP104 (ADHD), including its scheduling classification by the DrugEnforcement Agency in the United States, Shire's ability to benefit from itsacquisition of TKT, Shire's ability to secure new products forcommercialization and/or development and other risks and uncertainties detailedfrom time to time in Shire's filings with the Securities and ExchangeCommission, including its Annual Report on Form 10-K for the year to December31, 2004. 2Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire